Related by context. All words. (Click for frequent words.) 61 #Gy 60 cGy 59 5FU 58 EBRT 57 mcg kg 57 mg m² 56 MBq 56 #mg/m# [002] 56 mCi 55 preoperative chemotherapy 55 Gy fractions 55 μg 55 carboplatin paclitaxel 54 % CI #.#-#.# [003] 54 SUVmax 54 cisplatin 54 neoadjuvant 54 mg d 54 pCR 54 radical nephrectomy 54 neoadjuvant chemotherapy 54 intramuscularly 54 mitoxantrone 54 mcg mL 54 intraperitoneal injection 54 μmol L 53 severe neutropenia 53 biochemical relapse 53 mCi kg 53 pmol L 53 mg kg 53 ug mL 53 mGy 53 mg kg dose 53 P = .# 53 saline placebo 53 4mg/kg 53 adriamycin 53 fluorouracil 53 CR nPR 53 radiotherapy RT 53 chemoradiotherapy 53 nM 52 Median survival 52 mg/m2 52 FOLFOX 52 Q2W 52 microg 52 CR CRu 52 pegylated interferon alfa 2b 52 MADRS score 52 ABVD 52 mg m 52 nephrectomy 52 n = 52 ug kg 52 median PFS 52 mg/m2/day 52 g dL 52 rFSH 52 confidence interval CI 52 brain metastases 52 chemoradiation therapy 52 mmol kg 52 chemoradiation 52 pg ml 51 q# 51 % CI #.#-#.# [007] 51 pneumonectomy 51 #mg/kg [002] 51 ug ml 51 μg kg 51 mcg BID 51 #mg/m# [001] 51 cystectomy 51 5-FU/LV 51 adjuvant radiation 51 etoposide 51 pg mL 51 doxorubicin cyclophosphamide 51 IU ml 51 mL kg 51 locoregional 51 % Confidence Interval 51 achieved ACR# 51 lopinavir r 51 QRS duration 51 μSv 51 partial remissions 51 hypofractionated 51 p = #.# [003] 51 microgram kg 51 WBRT 51 external beam radiotherapy 51 androgen suppression 50 oral allopurinol 50 radiation therapy 50 preoperative radiotherapy 50 placebo dexamethasone 50 evaluable patients 50 sd = 50 mCi m 2 50 radiotherapy 50 8mg/kg 50 ALND 50 doxorubicin 50 ng ml 50 biochemical recurrence 50 comparator arm 50 gemcitabine carboplatin 50 invasive carcinomas 50 chlorambucil 50 BEACOPP 50 epirubicin cyclophosphamide 50 evaluable 50 daunorubicin 50 lumbar spine BMD 50 μg dose 50 mol L 50 debulking surgery 50 XELOX 50 log# 50 beam radiotherapy 50 lobectomy 50 progression TTP 50 hepatic metastases 50 kBq kg 50 timepoints 50 placebo p 50 lamivudine monotherapy 50 mg QD 50 TACE 50 FOLFIRI alone 50 g cm 50 plus medroxyprogesterone acetate 49 LVEF 49 p = NS 49 pT3 49 postintervention 49 adjuvant radiotherapy 49 tumor recurrence 49 lymphadenectomy 49 telaprevir dosed 49 placebo 49 uM 49 Partial Response 49 FOLFOX4 49 locoregional recurrence 49 F FDG PET 49 Flu Cy 49 mg TID 49 medroxyprogesterone acetate 49 CsA 49 sievert 49 postop 49 micromolar 49 cytoreduction 49 mmol L 49 intravenous REOLYSIN 49 mg kg ip 49 febrile neutropenia 49 crossclamp 49 RECIST criteria 49 peginterferon alfa 2a 49 dacarbazine 49 thyroglobulin 49 p = #.# [002] 49 mm3 49 PSA nadir 49 FOLFOX4 alone 49 TURBT 49 underwent surgical resection 49 QTcF 49 ng mL 49 androgen deprivation 49 epirubicin 49 Peg IFN 49 oral clodronate 49 lymphocytosis 49 dose cytarabine 49 HBeAg seroconversion 49 Doxil ® 49 tumor shrinkage 49 octreotide LAR 49 ng dL 49 μg mL 49 paclitaxel carboplatin 49 homozygotes 49 nmol L 49 carboplatin 49 ≥ 49 MACCE 49 tumor resection 49 % CI #.#-#.# [006] 49 AUC0 49 azathioprine 48 resection 48 neurologic progression 48 adjuvant chemotherapy 48 statistically significant p = 48 mg ustekinumab 48 lymph node metastasis 48 mitomycin 48 PaO 2 48 log# copies mL 48 underwent resection 48 mg/m2 IV 48 #mg QD [002] 48 postoperative chemotherapy 48 distant metastasis 48 mU liter 48 euthyroid 48 nodular partial response 48 p = 48 ipsilateral stroke 48 Median PFS 48 mcg albinterferon alfa 2b 48 pegylated liposomal doxorubicin 48 ropivacaine 48 ± 48 cyclophosphamide 48 hematologic toxicity 48 ^ sup 48 advanced adenomas 48 nmol liter 48 μg L 48 melphalan prednisone 48 adjuvant therapy 48 piperacillin tazobactam 48 mg/m2 dose 48 liver metastases 48 nodal metastases 48 preoperative PSA 48 radical cystectomy 48 % CI #.#-#.# [001] 48 postoperatively 48 cisplatin chemotherapy 48 baseline Hb 48 IFN alfa 48 tenecteplase 48 FDG uptake 48 unfractionated heparin 48 gemcitabine 48 verum acupuncture 48 interquartile range 48 receiving highly emetogenic 48 TIMP 48 Cmax 48 p = #.# [004] 48 abciximab 48 tirofiban 48 transurethral resection 48 Median progression 48 paclitaxel cisplatin 48 infarct size 48 cisplatin gemcitabine 48 χ 48 peg IFN 48 plus ribavirin 48 operable breast cancer 48 leukocyte count 48 μM 48 chemotherapy docetaxel 48 randomized 48 neoadjuvant therapy 48 estramustine 48 NMIBC 48 binary restenosis 48 histologically proven 48 lymph node metastases 48 surgical debulking 48 RBC transfusion 48 hepatic resection 48 q#h 48 dose dexamethasone 48 ALT elevation 48 mcg 48 mg simvastatin 47 preoperative 47 PSADT 47 nmol 47 ertapenem 47 baseline neutrophil counts 47 FOLFIRI 47 receiving VICTRELIS 47 log# IU mL 47 mg kg hr 47 plus dexamethasone 47 locoregional disease 47 lung metastases 47 vinorelbine 47 mg Lucentis 47 metastases 47 ASCT 47 micrometastases 47 docetaxel 47 creatinine ratio 47 p = .# [002] 47 fraction LVEF 47 liposomal doxorubicin 47 REYATAZ r arm 47 placebo p = 47 interferon alfa 2a 47 μL 47 extracapsular extension 47 diameter stenosis 47 retroperitoneal 47 Hb 47 μg ml 47 #mg BID [003] 47 Operative mortality 47 adjunctive placebo 47 care regimens CCR 47 mcg doses 47 infliximab monotherapy 47 pfu 47 remission CR 47 Folfox 47 definite stent thrombosis 47 goserelin 47 mrem 47 doxorubicin docetaxel 47 clodronate 47 #.#/#.# mm Hg [003] 47 #mg q8h 47 pretreatment baseline 47 peginterferon alfa 2b 47 ml kg 47 cyclophosphamide methotrexate 47 Hazard Ratio HR 47 FLT3 ITD 47 CC genotype 47 confidence interval #.#-#.# 47 endometrial thickness 47 axillary dissection 47 Kaplan Meier analysis 47 iodixanol 47 P ≤ 47 oblimersen 47 fluorouracil leucovorin 47 oxycodone CR 47 cytotoxic chemotherapy 47 lopinavir r arm 47 achieved statistical significance 47 trastuzumab 47 neutrophil counts 47 mg BID 47 % CI #.#-#.# [002] 47 leucopenia 47 adjuvant tamoxifen 47 concurrent chemoradiation 47 dexamethasone Decadron 47 antithymocyte globulin 47 reinfarction 47 dose escalation 47 endometrial carcinoma 47 nadroparin 47 free survival PFS 47 mW/cm2 47 pT2 47 randomisation 47 placebo PBO 47 sUA 47 intravenous bolus injection 47 relapsed CLL 47 fluence 47 contralateral 47 Pred Forte 47 distant metastases 47 randomized #:# 47 stage IIIb IV 47 GnRH agonist 47 subtrochanteric 47 Free Survival PFS 47 FOLFOX6 47 CCyR 47 TIMP 1 46 biopsy Gleason 46 #.#/#.# mmHg [001] 46 mU L 46 Adjuvant chemotherapy 46 pulmonary resection 46 mSv 46 endoscopic resection 46 Hgb 46 univariate analysis 46 nab paclitaxel 46 sirolimus eluting stent 46 methotrexate monotherapy 46 papillary renal cell carcinoma 46 TURP 46 tPSA 46 plus methotrexate 46 RYGB 46 -#.# log# 46 pmol 46 HBeAg positive 46 nonfatal MI 46 thyroidectomy 46 IFN α 46 confidence intervals CIs 46 baseline LDH 46 squamous histology 46 KRAS mutations occur 46 evaluable subjects 46 postoperative 46 conventional IMRT 46 pg g 46 esophagectomy 46 DOXIL 46 mu g 46 low dose cytarabine 46 keV 46 serum urate 46 androgen blockade 46 ug dose 46 low dose dexamethasone 46 PegIFN 46 FOLPI 46 enoxaparin 46 plus glycoprotein IIb 46 intraperitoneally 46 eptifibatide 46 mL/min/#.# m 2 46 histologically confirmed 46 tumor progression TTP 46 mL min 46 mEq L 46 recurrent VTE 46 intensity modulated radiotherapy IMRT 46 mcg QD 46 DAS# remission 46 patients evaluable 46 HER2 negative 46 uL 46 Response Evaluation Criteria 46 IIIa inhibitor 46 MGd 46 radical prostatectomy RP 46 resected 46 posttreatment 46 Solid Tumors RECIST 46 transplant ASCT 46 retinal thickness 46 x ULN 46 renal tumors 46 serum testosterone 46 mg p = 46 daily subcutaneous injections 46 6 mercaptopurine 46 peginterferon alfa 2a #KD 46 insulin detemir 46 partial nephrectomy 46 abacavir lamivudine 46 kDa 46 ABRAXANE therapy 46 elevated transaminases 46 bortezomib 46 ultrasonography 46 sustained virological response 46 leukopenia 46 prior chemotherapy regimens 46 CI -#.# 46 lispro 46 plus prednisone 46 ultrasonographic 46 localized renal 46 primary percutaneous coronary 46 EDSS scores 46 resectable 46 intratumoral 46 node dissection 46 gefitinib 46 mu m 46 tobramycin inhalation solution 46 SCr 46 femoral shaft fracture 46 BMS p = 45 g mL 45 DLTs 45 μg d 45 LV ejection fraction 45 mediastinal 45 Doppler sonography 45 undetectable HBV DNA 45 contralateral breast cancer 45 tamsulosin 45 micrometastasis 45 vasopressor 45 #.#mg/dL 45 cetuximab 45 neutrophil count 45 mL sec 45 Partial Responses 45 splenic 45 receiving ISENTRESS 45 dacarbazine chemotherapy 45 intravesical 45 intravitreal injections 45 IIIa inhibitors 45 intravesical therapy 45 CI = 45 -#.# ± [002] 45 total abdominal hysterectomy 45 micro sieverts 45 msec 45 #mg QD [001] 45 capecitabine 45 Hazard Ratio 45 cm2 45 rizatriptan 45 pegylated interferon 45 mAs 45 intravenous dosing 45 transaminase 45 total thyroidectomy 45 #F FDG 45 noninferiority 45 fig. S2 45 chemoembolization 45 prospectively randomized 45 azacitidine 45 ipsilateral 45 PREZISTA ritonavir 45 Kaplan Meier 45 pegIFN 45 clinically localized prostate 45 metastatic malignant melanoma 45 platinum refractory 45 pmol liter 45 Serum creatinine 45 AUCs 45 mg dose 45 mcg Albuferon 45 mg orally 45 CLL SLL 45 CHOP chemotherapy 45 multivariable analysis 45 sunitinib 45 salmeterol fluticasone propionate 45 ALT elevations 45 remission induction 45 ribavirin RBV 45 mg/# h 45 â ‰ ¥ 45 extrapleural pneumonectomy 45 DMARD 45 axillary lymph node dissection 45 virologic response 45 axillary node dissection 45 mycophenolate mofetil 45 ipsilateral breast 45 gemcitabine cisplatin 45 mRCC 45 q8h 45 mRNA expression 45 PEG IFN 45 randomization 45 hip BMD 45 histologically 45 pyrazinamide 45 kGy 45 subcutaneous injections 45 imetelstat 45 dimensional echocardiography 45 cytoreductive nephrectomy 45 IELT 45 ACR# response 45 5 FU 45 atheroma volume 45 leuprorelin 45 median survivals 45 DAPT 45 melphalan 45 mg/m2 administered 45 dosing cohorts 45 mg kg IV 45 pelvic radiotherapy 45 #.#x# [002] 45 Irinotecan 45 serum prostate 45 recurrent venous thromboembolism 45 radiochemotherapy 45 intraperitoneal therapy 45 Fludara 45 immunoreactive 45 hours postdose 45 intramuscular injections 45 cm -2 45 topotecan 45 male Wistar rats 45 breast carcinoma 45 orchiectomy 45 undetectable HCV RNA 45 3mg 45 hemoglobin Hb 45 gemcitabine chemotherapy 45 cm H2O 45 aspartate aminotransferase 45 ‰ ¥ 45 gadolinium enhanced 45 5-fluorouracil/leucovorin 45 EDSS score 45 intensity modulated radiation 45 tamoxifen therapy 45 cytoreductive surgery 45 invasive coronary angiography 44 dB insertion loss 44 ventricular myocardium 44 Viread Emtriva Sustiva 44 mM 44 mmol 44 certolizumab 44 renal pelvis 44 λ 44 fractional shortening 44 serum phosphorus 44 lymph node involvement 44 intradermal injections 44 paroxysmal AF 44 lymphovascular invasion 44 statistically significant p 44 cisplatin vinorelbine 44 CRp 44 3mg/kg 44 budesonide pMDI 44 HBeAg negative 44 death reinfarction 44 intra articular injection 44 hyperintensity 44 lymphocyte count 44 CD# + [002] 44 telaprevir dosing 44 curative resection 44 plasma concentrations 44 Wistar rats 44 detectable HCV RNA 44 SLNB 44 CrCl 44 RECIST Response Evaluation Criteria 44 secondary efficacy endpoint 44 achieved PASI 44 refractory NSCLC 44 SLN biopsy 44 Sprague Dawley rats 44 metastatic GIST 44 mg q8h 44 irbesartan 44 mg 44 squamous cell carcinoma SCC 44 Complete Response CR 44 ng dl 44 liver metastasis 44 HIV RNA 44 docetaxel chemotherapy 44 nodal dissection 44 IQR 44 FFNS 44 IU mL 44 para aortic 44 PegIFN RBV 44 advanced adenoma 44 micrograms mL 44 univariate 44 #mg/day [002] 44 transaminase elevations 44 luminal 44 CK MB 44 dalteparin 44 5 fluorouracil 44 oxycodone IR 44 iniparib BSI 44 serum cortisol 44 paclitaxel 44 mmHg p = 44 Taxus Stent 44 ALT normalization 44 bevacizumab 44 ml min 44 temozolomide 44 #.#mg/kg [002] 44 FEV1 44 peritoneal 44 wedge resection 44 LPV r 44 androgen ablation 44 HER2 positive tumors 44 nondiabetic patients 44 interferon alfa 44 mg administered orally 44 stereotactic radiosurgery SRS 44 cytogenetic abnormalities 44 metastatic RCC 44 liver resection 44 nadolol 44 hypophosphatemia 44 ALA PDT 44 NSTE ACS 44 lymph node dissection 44 peginterferon 44 1mg 44 postmenopausal osteoporotic women 44 antiangiogenic therapy 44 mesalamine granules 44 metachronous 44 Zometa hazard 44 Metastatic 44 radical prostatectomy 44 Ceplene/IL-2 44 mL/min/#.# m2 44 adefovir 44 subcutaneous dose 44 deferoxamine 44 docetaxel prednisone 44 dosimetric 44 nonresponders 44 nmol l 44 intraperitoneal 44 left ventricular LV 44 K + ATPase 44 nonfatal myocardial infarction 44 NIHSS 44 nonsignificant 44 curve AUC 44 Thal Dex 44 target vessel revascularization 44 log# reduction 44 splenectomized patients 44 acneform rash 44 plus GP IIb 44 virologic failure 44 Index CDAI 44 μl 44 #μg [002] 44 Vancocin p = 44 sustained virologic response 44 infarct 44 post operatively 44 epoetin alfa 44 bolus dose 44 imatinib therapy 44 cells mcL 44 echogenic 44 mcg dose 44 Hazard Ratio = 44 methylprednisolone 44 intravitreal injection 44 conjugated equine estrogen 44 adenoma 44 cm sec 44 gemcitabine Gemzar 44 hepatectomy 44 HDRS 44 subcutaneous doses 44 pegylated interferon alfa 2a 44 periprocedural 44 mmol l 44 nH 44 thromboembolic 44 prospectively evaluated 44 mg/# hours 44 Postoperative 44 ABC/3TC 44 fallopian tube carcinoma 44 lenalidomide dexamethasone 44 oral diclofenac 44 #.#-#.# [011] 44 p ≤ 44 axillary lymph node 44 recurrent glioblastoma multiforme 44 systolic BP 44 dose melphalan 44 multivariate Cox 44 bendamustine 44 alpha 2a 44 vertebrobasilar 44 preoperatively 44 bolus injection 43 LAB GHRH 43 oral prednisone 43 Supplementary Table 43 achieved sustained virologic 43 mIU ml 43 stage IIIB 43 dexamethasone 43 pancreatic adenocarcinoma 43 biologic DMARD 43 alanine aminotransferase ALT 43 hemoglobin concentration 43 colorectal liver metastases 43 retropubic 43 SVR# 43 active comparator 43 radioiodine therapy 43 nephron sparing surgery 43 mg kg Hematide 43 g dl 43 neoadjuvant treatment 43 ErbB2 positive 43 ovarian carcinoma 43 interferon ribavirin 43 undergoing coronary angiography 43 fallopian tube cancers 43 prostate carcinoma 43 radiation chemoradiation 43 symptomatic VTE 43 multicenter randomized controlled 43 RVOT 43 antiandrogen 43 axillary nodes 43 etanercept 43 ribavirin therapy 43 male Sprague Dawley 43 Kaplan Meier estimates 43 -#.# mg dL [002] 43 #mg BID [001] 43 ATV RTV 43 biventricular repair 43 anastrazole 43 MMSE score 43 clopidogrel 43 μmol 43 interferon alfa 2b 43 Left Ventricular Ejection Fraction 43 infarcts 43 preintervention 43 randomized #:#:# 43 angiographic restenosis 43 fluticasone salmeterol 43 resections 43 highest tertile 43 mg RDEA# 43 chemotherapy cisplatin 43 genotypic resistance 43 ± SD 43 mammographic density 43 complete remissions 43 tacrolimus ointment 43 bupivacaine 43 mcg linaclotide 43 Fig. 2A 43 ìg 43 fluoropyrimidine 43 creatinine clearance 43 milligrams mg 43 neutropaenia 43 seronegative 43 DOXIL ® 43 HSCT 43 eplerenone 43 #.#ng/ml 43 contralateral breast 43 cm 43 HCV genotype 43 mL 43 HoLEP 43 μg l 43 chemoresistant 43 therapy IMRT 43 annualized relapse 43 induration 43 nontreated 43 seminal vesicle invasion 43 nonobese 43 T2 weighted 43 colectomy 43 IMRT treatments 43 ULN 43 Pharmacokinetics PK 43 APTIVUS r 43 alanine aminotransferase 43 composite endpoint 43 mg qd 43 intraventricular 43 estrogen receptor progesterone receptor 43 intramuscular dose 43 allogeneic SCT 43 ara C 43 myeloablative 43 IMRT 43 DMARDs 43 CIMZIA TM 43 nonmetastatic prostate cancer 43 systemic embolism 43 adefovir treated 43 FDG-PET/CT 43 sleeve lobectomy 43 VELCADE melphalan 43 liver histology 43 gadolinium enhancing lesions 43 mol 43 HBeAg negative patients 43 IPSS 43 incontinence episodes 43 rapid virologic response 43 mIU mL 43 retrospectively analyzed 43 mRS 43 plus MTX 43 mEq 43 Fig. 1D 43 kilogram mg kg 43 hypogonadal 43 normothermic 43 gastrectomy 43 seroconversion 43 chronic GVHD 43 ANOVA 43 #.#g/day 43 peripheral blood mononuclear 43 LEXIVA r 43 intraobserver 43 seropositivity 43 pegylated interferon ribavirin 43 elective PCI 43 axillary node 43 esophageal carcinoma 43 splenectomized 43 subcutaneously 43 ritonavir boosted atazanavir 43 intravenous bolus 43 proximal DVT 43 androgen suppression therapy 43 administered subcutaneously 43 injected subcutaneously 43 morphometric vertebral fractures 43 patients undergoing CABG 43 seminal vesicles 43 intravenous dose 43 zonisamide SR 43 serum concentrations 43 hormonal therapy 43 Psoriasis Area 43 cefazolin 43 HAM D# scores 43 eribulin 43 cyclophosphamide chemotherapy 43 TEAEs 43 medically inoperable 43 nonmetastatic 43 saline injections 43 #ug [001] 43 -#.# log# copies mL 43 ER CHOP 43 transitional cell carcinoma 43 κ 43 Cisplatin 43 ischemia driven 43 mK 43 μg liter 43 kBq 43 statistical significance p 43 zoledronic acid 43 relapsed MM 43 prospectively defined 43 IV NSCLC 43 deoxy 43 flutamide 43 lactate dehydrogenase LDH 43 nmol L. 43 sentinel lymph node biopsy 43 viral kinetics 43 azacytidine 43 serum ALT 43 G CSF 43 tumor regressions 43 nonmyeloablative 43 trials RCTs 43 sieverts 43 σ 43 fludarabine 43 RGT arm 43 racemic albuterol 43 Adjuvant therapy 43 nicardipine 43 unresectable 43 mcg kg min 43 μg dL 43 venography 43 metastatic lesion 43 ritonavir boosted 43 urinary excretion 43 postoperative radiotherapy 43 logMAR 43 GISTs 43 DMARD therapy 43 Â ± 43 sarcomatoid 43 triamcinolone 43 achieved mucosal healing 43 μsec 43 unfractionated heparin UFH 43 #mg BID [002] 42 Secondary endpoints included 42 epithelial ovarian cancer 42 metastatic lesions 42 micromoles 42 angiotensin converting enzyme inhibitor 42 supraclavicular